Because the EGFR inhibitor suppressed CD44v expression even in KRAS-mutated cancer cells, the EGFR inhibitors could also be applicable to the KRAS-mutated tumours to target the drug-tolerant CD44v-positive cancer cells. This evidence concerns the gene KRAS and cancer.